[go: up one dir, main page]

NI201500096A - Compuesto químicos - Google Patents

Compuesto químicos

Info

Publication number
NI201500096A
NI201500096A NI201500096A NI201500096A NI201500096A NI 201500096 A NI201500096 A NI 201500096A NI 201500096 A NI201500096 A NI 201500096A NI 201500096 A NI201500096 A NI 201500096A NI 201500096 A NI201500096 A NI 201500096A
Authority
NI
Nicaragua
Prior art keywords
chemical compounds
compounds
processes
formula
preparation
Prior art date
Application number
NI201500096A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
Berry David
Delouvrie Benedicte
Steven Harris Craig
Marie Paul Lambert - Van Der Brempt Christine
Ouvry Gilles
Patrick Reid Gary
Peter Tomkinson Gary
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201500096A publication Critical patent/NI201500096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con compuestos de Fórmula (I) o sales farmacéuticamente aceptables de los mismos, en donde R1 y R2 tienen cualquiera de los significados definidos anteriormente en la presente en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos proliferativos celulares.
NI201500096A 2013-01-23 2015-07-22 Compuesto químicos NI201500096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23

Publications (1)

Publication Number Publication Date
NI201500096A true NI201500096A (es) 2016-02-16

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500096A NI201500096A (es) 2013-01-23 2015-07-22 Compuesto químicos

Country Status (26)

Country Link
US (2) US9156831B2 (es)
EP (1) EP2948447B1 (es)
JP (1) JP6307096B2 (es)
KR (1) KR102202516B1 (es)
CN (1) CN104936953B (es)
AP (1) AP2015008604A0 (es)
AR (1) AR094553A1 (es)
AU (1) AU2014208964B2 (es)
BR (1) BR112015017331B1 (es)
CA (1) CA2897279C (es)
CL (1) CL2015002027A1 (es)
CR (1) CR20150367A (es)
DO (1) DOP2015000170A (es)
ES (1) ES2608395T3 (es)
IL (1) IL239890A0 (es)
MA (1) MA38287B1 (es)
MX (1) MX361136B (es)
NI (1) NI201500096A (es)
PE (1) PE20151979A1 (es)
PH (1) PH12015501584A1 (es)
RU (1) RU2644769C2 (es)
SG (1) SG11201505631PA (es)
TN (1) TN2015000313A1 (es)
TW (1) TWI606047B (es)
UY (1) UY35275A (es)
WO (1) WO2014114928A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN107137405A (zh) * 2017-04-14 2017-09-08 黄德莲 一种治疗肾炎的药物组合物
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
US12343380B2 (en) 2018-11-05 2025-07-01 Iovance Biotherapeutics, Inc. Expansion of TILs utilizing AKT pathways inhibitors
EP3877380A1 (en) 2018-11-05 2021-09-15 Syngenta Participations Ag Pesticidally active azole-amide compounds
ES2953140T3 (es) 2019-03-08 2023-11-08 Syngenta Crop Protection Ag Compuestos de azol-amida activos de manera plaguicida
BR112021018495A2 (pt) 2019-03-20 2021-11-30 Syngenta Crop Protection Ag Compostos de azolamida ativos em termos pesticidas
US20220213063A1 (en) 2019-03-22 2022-07-07 Syngenta Crop Protection Ag N-[l-(5-BROMO-2-PYRIMIDIN-2-YL-1,2,4-TRIAZOL-3-YL)ETHYL]-2-CYCLOPROPYL-6-(TRIFLUOROMETHYL)PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES
JP2023522247A (ja) 2020-04-24 2023-05-29 アストラゼネカ・アクチエボラーグ 医薬製剤

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (es) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP3028168B2 (ja) 1993-03-29 2000-04-04 住化ファインケム株式会社 ベンゼンスルホンアミド誘導体の製造方法
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
RO115522B1 (ro) 1995-02-02 2000-03-30 Smithkline Beecham P.L.C. Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
CA2260900A1 (en) 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo pyridazine derivatives as inverse agonists of the gabaa.alpha.5 receptor subtype
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
EP1303507A1 (en) 2000-07-19 2003-04-23 F. Hoffmann-La Roche Ag Pyrimidine derivatives
EP1446387B1 (en) 2001-11-21 2009-11-04 Pharmacia & Upjohn Company LLC Substituted aryl 1,4-pyrazine derivatives
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
PT1704145E (pt) 2004-01-12 2012-09-04 Ym Biosciences Australia Pty Inibidores de quinase seletivos
EP1742935B1 (en) 2004-04-13 2010-02-24 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
WO2006065601A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
HRP20130429T1 (en) 2005-06-10 2013-06-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
CN101479255B (zh) 2006-03-22 2013-05-01 沃泰克斯药物股份有限公司 用于治疗增殖性病症的c-MET蛋白激酶抑制剂
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
CL2007002123A1 (es) 2006-07-21 2008-06-13 Irm Llc Compuestos derivados de heteroaril-1h-pirazol, utiles como moduladores del desarrollo y funcion de los linfocitos b.
MY148688A (en) 2006-08-23 2013-05-31 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
US8119671B2 (en) 2007-03-07 2012-02-21 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pest control agent
MX2010001746A (es) 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Pirimidinas biciclicas fusionadas.
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
RS53552B1 (en) 2007-10-11 2015-02-27 Astrazeneca Ab DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B
CA2703653A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
US8268754B2 (en) 2007-12-07 2012-09-18 Nissan Chemical Industries, Ltd. Substituted dihydroazole compound and pest control agent
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
JP2011507848A (ja) 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのベンゾピランおよびアナログ
EP2310391A1 (en) * 2008-06-27 2011-04-20 S*BIO Pte Ltd Pyrazine substituted purines
EP2342190A1 (en) 2008-09-02 2011-07-13 Novartis AG Bicyclic kinase inhibitors
JP2010083883A (ja) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2010063863A (ja) 2008-09-11 2010-03-25 Mugen:Kk ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法
CN101676271B (zh) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 含有不饱和杂环胺的四环素衍生物
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
PT2356113E (pt) * 2008-11-14 2015-04-14 Bayer Ip Gmbh Compostos arilo substituídos heterociclicamente como inibidores de hif
KR101958632B1 (ko) * 2008-12-19 2019-03-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
ES2435804T3 (es) * 2009-02-13 2013-12-23 Bayer Intellectual Property Gmbh Pirimidinas condensadas como inhibidores de Akt
AU2010213192A1 (en) 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
WO2011048082A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
SG182803A1 (en) 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
JP2011178673A (ja) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd 非農園芸害虫の防除方法
NZ718622A (en) 2010-03-30 2018-03-23 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
JP5954838B2 (ja) * 2010-09-14 2016-07-20 エクセリクシス， インク． Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法
SG188302A1 (en) * 2010-09-16 2013-04-30 Hutchison Medipharma Ltd Fused heteroaryls and their uses
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
WO2013049591A2 (en) 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
RS56673B1 (sr) 2012-04-05 2018-03-30 Vertex Pharma Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste

Also Published As

Publication number Publication date
CL2015002027A1 (es) 2015-11-13
RU2015132370A (ru) 2017-03-02
US9156831B2 (en) 2015-10-13
BR112015017331B1 (pt) 2022-01-11
IL239890A0 (en) 2015-08-31
US9657008B2 (en) 2017-05-23
CN104936953B (zh) 2017-03-08
PE20151979A1 (es) 2016-01-15
BR112015017331A2 (pt) 2017-07-11
CN104936953A (zh) 2015-09-23
TWI606047B (zh) 2017-11-21
US20160137634A1 (en) 2016-05-19
UY35275A (es) 2014-07-31
WO2014114928A1 (en) 2014-07-31
KR102202516B1 (ko) 2021-01-12
US20140206700A1 (en) 2014-07-24
AU2014208964B2 (en) 2016-09-01
DOP2015000170A (es) 2015-08-16
CA2897279A1 (en) 2014-07-31
RU2644769C2 (ru) 2018-02-14
EP2948447B1 (en) 2016-09-21
MA38287A1 (fr) 2018-01-31
CA2897279C (en) 2020-12-29
JP2016508484A (ja) 2016-03-22
TN2015000313A1 (en) 2017-01-03
EP2948447A1 (en) 2015-12-02
TW201522329A (zh) 2015-06-16
AU2014208964A1 (en) 2015-08-06
CR20150367A (es) 2015-10-20
SG11201505631PA (en) 2015-08-28
JP6307096B2 (ja) 2018-04-04
MA38287B1 (fr) 2018-08-31
KR20150109385A (ko) 2015-10-01
BR112015017331A8 (pt) 2019-11-12
AP2015008604A0 (en) 2015-07-31
PH12015501584A1 (en) 2015-10-05
AR094553A1 (es) 2015-08-12
HK1214592A1 (en) 2016-07-29
MX361136B (es) 2018-11-28
ES2608395T3 (es) 2017-04-10
MX2015009465A (es) 2015-09-28

Similar Documents

Publication Publication Date Title
NI201500167A (es) Compuestos químicos
NI201500096A (es) Compuesto químicos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
CR20150326A (es) Inhibidores de autotaxina
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
ECSP14013215A (es) Compuestos novedosos
ECSP16074478A (es) Compuestos novedosos
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX2016006509A (es) Compuestos triciclicos de piperidina.
GT201500189A (es) Inhibidores de autotaxina
CU20150048A7 (es) Compuestos heteroaromáticos como ligandos d1 de dopamina